Pathologists Use Spatial Light Interference Microscopy to Predict Risk of Prostate Cancer Recurrence Prior to Biopsy or Surgery
|
By LabMedica International staff writers Posted on 24 May 2015 |

Image: Left: Quantitative phase image of an unstained prostatectomy sample from a patient who had a biochemical recurrence of prostate cancer. Right: A zoomed-in region from the quantitative phase image showing a cancerous gland with debris in the lumen. The stroma, or supportive tissue environment, shows discontinuities in the fiber length and disorganization in the orientation of the fibers (Photo courtesy of the University of Illinois).
A novel microscopy method that combines phase contrast microscopy with holography enables prediction of the likelihood of prostate cancer recurrence prior to biopsy or surgery.
The method is called spatial light interference microscopy or SLIM. SLIM uses a commercial phase contrast microscope and white light illumination, resulting in nanometer scale sensitivity to optical path-length shifts. In essence, SLIM combines phase contrast microscopy with holography.
Investigators at the University of Illinois (Urbana, USA) have introduced a new instrument for SLIM imaging. Their real-time fast SLIM technique could image at a maximum rate of 50 frames per second and provided real-time quantitative phase images at 12.5 frames per second. They were able to achieve this fast rate by combining rapid LCPM (linear pulse-code modulation) and a fast sCMOS camera. In addition, they developed the software to perform phase reconstruction and display the quantitative phase images in real-time.
In the current study, the investigators used the SLIM technique to examine 181 tissue samples obtained from the [US] National Cancer Institute-sponsored Cooperative Prostate Tissue Resource (CPCTR), The specimens were taken from individuals who had a prostatectomy, approximately half who had no recurrence and half who did.
The instrument was programmed to scan microscope slides containing 320–360 individual cores. The resulting SLIM image contained rich information about tissue morphology, with the glandular epithelium and stroma structures clearly resolved. This allowed the investigators to interrogate scattering changes specific to prostate stroma.
Results suggested that SLIM showed promise in assisting pathologists to improve prediction of prostate cancer recurrence. The data revealed that a lower value of anisotropy corresponded to a higher risk for recurrence, meaning that the stroma adjoining the glands of recurrent patients was more fractionated than in non-recurrent patients. Anisotropy is the property of being directionally dependent, as opposed to isotropy, which implies identical properties in all directions. It can be defined as a difference, when measured along different axes, in a material's physical or mechanical properties.
"For every 20 surgery procedures to take out the prostate, it is estimated that only one life is saved," said senior author Dr. Gabriel Popescu, associate professor of electrical and computer engineering at the University of Illinois. "For the other 19 people, they would be better left alone, because with removing the prostate, the quality of life goes down dramatically. So if you had a tool that could tell which patient will actually be more likely to have a bad outcome, then you could more aggressively treat that case."
"What SLIM is very good at is to make invisible objects visible with nanoscale sensitivity," said Dr. Popescu. "So we pick these structural details without the need for staining, which can introduce new variables into the specimen. Our dream is for everyone to have SLIM capabilities in their labs. One can imagine that a SLIM-based tissue imager will scan biopsies in a clinic and, paired with software that is intelligent enough to look for these specific markers, will provide the pathologist with valuable new information. This additional information will translate into more accurate diagnosis and prognosis."
The paper describing the use of SLIM to predict prostate cancer recurrence was published in the May 15, 2015, online edition of the journal Scientific Reports.
Related Links:
University of Illinois
The method is called spatial light interference microscopy or SLIM. SLIM uses a commercial phase contrast microscope and white light illumination, resulting in nanometer scale sensitivity to optical path-length shifts. In essence, SLIM combines phase contrast microscopy with holography.
Investigators at the University of Illinois (Urbana, USA) have introduced a new instrument for SLIM imaging. Their real-time fast SLIM technique could image at a maximum rate of 50 frames per second and provided real-time quantitative phase images at 12.5 frames per second. They were able to achieve this fast rate by combining rapid LCPM (linear pulse-code modulation) and a fast sCMOS camera. In addition, they developed the software to perform phase reconstruction and display the quantitative phase images in real-time.
In the current study, the investigators used the SLIM technique to examine 181 tissue samples obtained from the [US] National Cancer Institute-sponsored Cooperative Prostate Tissue Resource (CPCTR), The specimens were taken from individuals who had a prostatectomy, approximately half who had no recurrence and half who did.
The instrument was programmed to scan microscope slides containing 320–360 individual cores. The resulting SLIM image contained rich information about tissue morphology, with the glandular epithelium and stroma structures clearly resolved. This allowed the investigators to interrogate scattering changes specific to prostate stroma.
Results suggested that SLIM showed promise in assisting pathologists to improve prediction of prostate cancer recurrence. The data revealed that a lower value of anisotropy corresponded to a higher risk for recurrence, meaning that the stroma adjoining the glands of recurrent patients was more fractionated than in non-recurrent patients. Anisotropy is the property of being directionally dependent, as opposed to isotropy, which implies identical properties in all directions. It can be defined as a difference, when measured along different axes, in a material's physical or mechanical properties.
"For every 20 surgery procedures to take out the prostate, it is estimated that only one life is saved," said senior author Dr. Gabriel Popescu, associate professor of electrical and computer engineering at the University of Illinois. "For the other 19 people, they would be better left alone, because with removing the prostate, the quality of life goes down dramatically. So if you had a tool that could tell which patient will actually be more likely to have a bad outcome, then you could more aggressively treat that case."
"What SLIM is very good at is to make invisible objects visible with nanoscale sensitivity," said Dr. Popescu. "So we pick these structural details without the need for staining, which can introduce new variables into the specimen. Our dream is for everyone to have SLIM capabilities in their labs. One can imagine that a SLIM-based tissue imager will scan biopsies in a clinic and, paired with software that is intelligent enough to look for these specific markers, will provide the pathologist with valuable new information. This additional information will translate into more accurate diagnosis and prognosis."
The paper describing the use of SLIM to predict prostate cancer recurrence was published in the May 15, 2015, online edition of the journal Scientific Reports.
Related Links:
University of Illinois
Latest Pathology News
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Channels
Clinical Chemistry
view channel
Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
Accurate diabetes detection is essential because early identification guides timely management, yet test performance can vary in people with hemoglobin variants such as sickle cell trait.... Read more
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more




 Assay.jpg)



